Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives $10.00 Consensus PT from Analysts

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) have earned an average recommendation of “Moderate Buy” from the five analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $10.00.

VTYX has been the subject of a number of recent research reports. Oppenheimer reiterated an “outperform” rating and issued a $9.00 price objective (down from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. HC Wainwright reissued a “neutral” rating and set a $6.00 price objective on shares of Ventyx Biosciences in a report on Monday, November 11th.

Insider Transactions at Ventyx Biosciences

In other news, insider John Nuss sold 13,161 shares of the business’s stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $2.26, for a total transaction of $29,743.86. Following the sale, the insider now directly owns 485,701 shares in the company, valued at approximately $1,097,684.26. The trade was a 2.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Raju Mohan purchased 261,752 shares of the stock in a transaction on Monday, November 25th. The stock was acquired at an average cost of $2.01 per share, for a total transaction of $526,121.52. Following the acquisition, the chief executive officer now directly owns 2,175,028 shares in the company, valued at approximately $4,371,806.28. This trade represents a 13.68 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 18.18% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Ventyx Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in VTYX. Acadian Asset Management LLC bought a new position in Ventyx Biosciences during the 2nd quarter valued at about $608,000. Vestal Point Capital LP raised its stake in shares of Ventyx Biosciences by 31.2% in the third quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $3,760,000 after acquiring an additional 410,000 shares during the last quarter. Deerfield Management Company L.P. Series C raised its stake in shares of Ventyx Biosciences by 64.6% in the second quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock valued at $13,466,000 after acquiring an additional 2,287,570 shares during the last quarter. Sio Capital Management LLC boosted its holdings in shares of Ventyx Biosciences by 153.2% in the 3rd quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company’s stock worth $4,299,000 after acquiring an additional 1,193,024 shares in the last quarter. Finally, Cubist Systematic Strategies LLC grew its position in Ventyx Biosciences by 165.8% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 149,500 shares of the company’s stock worth $345,000 after acquiring an additional 93,247 shares during the last quarter. Institutional investors and hedge funds own 97.88% of the company’s stock.

Ventyx Biosciences Stock Down 0.9 %

VTYX stock opened at $2.28 on Tuesday. The firm has a 50 day moving average of $2.30 and a two-hundred day moving average of $2.40. Ventyx Biosciences has a 12 month low of $1.67 and a 12 month high of $11.48. The company has a market capitalization of $161.22 million, a price-to-earnings ratio of -0.97 and a beta of 0.48.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.